Ahmet Emre Eskazan (A Emre Eskazan, Ahmet Emre Eşkazan)

Scopus Author ID Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 91

Top Venues

Expert review of hematology

Turkish journal of haematology : official journal of Turkish Society of Haematology

Oncology and therapy

Cancer

Istanbul University Cerrahpaşa

Istanbul University Cerrahpasa Faculty of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Istanbul University Cerrahpaşa

Turkey

Associate Professor :: Department of Internal Medicine, Division of Hematology

Education History

Istanbul University Cerrahpasa Faculty of Medicine

Turkey

PHD

Publications

Selin Küçükyurt, Tuğçe Eşkazan, Mesut Ayer, Burçak Kılıçkıran Avcı, İbrahim Hatemi, Ahmet Emre Eskazan
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP. Pleura and peritoneum 9 (1) (2024)
Betül Saydan, Deniz Özmen, Ahmet Emre Eskazan
Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase? Expert review of hematology 17 (7) (2024)
Deniz Özmen, Duygu Demet Alpaydın, Muhammed Ali Saldoğan, Ahmet Emre Eskazan
A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia. Expert opinion on drug safety (2024)
Deniz Özmen, Duygu Demet Alpaydın, Muhammed Ali Saldoğan, Ahmet Emre Eskazan
A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia. Expert opinion on drug safety 23 (4) (2024)
Betül Saydan, Deniz Ozmen, Ahmet Emre Eskazan
Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase? Expert review of hematology (2024)
Umut Yılmaz, Selin Küçükyurt, Muhlis Cem Ar, Ahmet Emre Eskazan
Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think? Oncology and therapy (2024)
Umut Yılmaz, Selin Küçükyurt, Muhlis Cem Ar, Ahmet Emre Eskazan
Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think? Oncology and therapy 12 (1) (2024)
Zehra Narlı Özdemir, Yıldız İpek, Pusem Patir, Gözde Ermiş, Rafiye Ciftciler, Deniz Özmen, Mehmet Baysal, Vildan Gursoy, Esra Yıldızhan, Serkan Güven, Tarık Ercan, Tayfun Elibol, Sinan Mersin, Eylem Genç, Eren Arslan Davulcu, Volkan Karakus, Nergiz Erkut, Gürsel Güneş, Reyhan Diz Küçükkaya, Ahmet Emre Eskazan
Impact of CALR and JAK2 V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients. Turkish journal of haematology : official journal of Turkish Society of Haematology 41 (1) (2024)
Betül Saydan, Deniz Özmen, Ahmet Emre Eskazan
Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase? Expert review of hematology (2024)
Deniz Özmen, Duygu Demet Alpaydın, Muhammed Ali Saldoğan, Ahmet Emre Eskazan
A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia. Expert opinion on drug safety 23 (4) (2024)
Selin Küçükyurt, Tuğçe Eşkazan, Mesut Ayer, Burçak Kılıçkıran Avcı, İbrahim Hatemi, Ahmet Emre Eskazan
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP. Pleura and peritoneum 9 (1) (2024)
Zehra Narlı Özdemir, Yıldız İpek, Pusem Patir, Gözde Ermiş, Rafiye Ciftciler, Deniz Özmen, Mehmet Baysal, Vildan Gursoy, Esra Yıldızhan, Serkan Güven, Tarık Ercan, Tayfun Elibol, Sinan Mersin, Eylem Genç, Eren Arslan Davulcu, Volkan Karakus, Nergiz Erkut, Gürsel Güneş, Reyhan Diz Küçükkaya, Ahmet Emre Eskazan
Impact of CALR and JAK2 V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients. Turkish journal of haematology : official journal of Turkish Society of Haematology 41 (1) (2024)
Umut Yılmaz, Selin Küçükyurt, Muhlis Cem Ar, Ahmet Emre Eskazan
Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think? Oncology and therapy 12 (1) (2024)
Deniz Özmen, Duygu Demet Alpaydın, Muhammed Ali Saldoğan, Ahmet Emre Eskazan
A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia. Expert opinion on drug safety (2024)
Ece Vural, Tuğrul Elverdi, Ayşe Salihoğlu, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Teoman Soysal, Ahmet Emre Eskazan
Complications of therapeutic plasma exchange: A retrospective, single-center study of 2505 procedures performed in 338 patients over 15 years. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2024)
Zehra Narlı Özdemir, Yıldız İpek, Pusem Patir, Gözde Ermiş, Rafiye Ciftciler, Deniz Özmen, Mehmet Baysal, Vildan Gursoy, Esra Yıldızhan, Serkan Güven, Tarık Ercan, Tayfun Elibol, Sinan Mersin, Eylem Genç, Eren Arslan Davulcu, Volkan Karakus, Nergiz Erkut, Gürsel Güneş, Reyhan Diz Küçükkaya, Ahmet Emre Eskazan
Impact of CALR and JAK2 V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients. Turkish journal of haematology : official journal of Turkish Society of Haematology 41 (1) (2024)
Zehra Narlı Özdemir, Yıldız İpek, Pusem Patir, Gözde Ermiş, Rafiye Ciftciler, Deniz Özmen, Mehmet Baysal, Vildan Gursoy, Esra Yıldızhan, Serkan Güven, Tarık Ercan, Tayfun Elibol, Sinan Mersin, Eylem Genç, Eren Arslan Davulcu, Volkan Karakus, Nergiz Erkut, Gürsel Güneş, Reyhan Diz Küçükkaya, Ahmet Emre Eskazan
Impact of CALR and JAK2 V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients. Turkish journal of haematology : official journal of Turkish Society of Haematology 41 (1) (2024)
Mehmet Baysal, Meltem Bayrak, Ahmet Emre Eskazan
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Expert review of hematology 16 (2) (2023)
Reyhan Yılmaz, Ahmet Emre Eskazan
Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting. Future oncology (London, England) (2023)
Duygu Seyhan Erdoğan, Gülçin Benbir Şenel, Ayşegül Gündüz, Beria Peren Uçar, Tuğrul Elverdi, Ayşe Salihoğlu, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Ahmet Emre Eskazan
A cross-sectional study on restless legs syndrome (RLS) in polycythemia vera (PV): is iron deficiency the only culprit? Neurological research (2023)
Sümbül Gezer, Zeliha Emrence, Tuğrul Elverdi, Muhlis Cem Ar, Burcu Salman Yaylaz, Ferda Paçal, Ayşegül Ünüvar, Melda Sarıman, Ahmet Emre Eskazan, Serap Karaman, Ayşe Salihoğlu, Zeynep Karakaş, Neslihan Abacı, Sema Sırma Ekmekçi
Upregulation of SPINK2 in acute myeloid leukemia. Advances in laboratory medicine 4 (1) (2023)
Emine Eylem Genç, İrem Sena Saraç, Hayrunnisa Arslan, Ahmet Emre Eskazan
Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial. Oncology and therapy (2023)
Emine Eylem Genç, İrem Sena Saraç, Hayrunnisa Arslan, Ahmet Emre Eskazan
Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial. Oncology and therapy (2023)
Mehmet Baysal, Meltem Bayrak, Ahmet Emre Eskazan
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Expert review of hematology (2023)
Mehmet Baysal, Meltem Bayrak, Ahmet Emre Eskazan
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Expert review of hematology (2023)
Sinan Mersin, Fatih Gülük, Emirhan Gülcan, Ahmet Emre Eskazan
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults. Expert opinion on pharmacotherapy (2023)
Mehmet Baysal, Meltem Bayrak, Ahmet Emre Eskazan
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Expert review of hematology 16 (2) (2023)
Ahmet Emre Eskazan
Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted! Cancer (2023)
Eda Nuhoğlu Kantarcı, Ece Tolgay, Ahmet Emre Eskazan
Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient. Cancer (2023)
Mehmet Baysal, Meltem Bayrak, Ahmet Emre Eskazan
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Expert review of hematology 16 (2) (2023)
Sümbül Gezer, Zeliha Emrence, Tuğrul Elverdi, Muhlis Cem Ar, Burcu Salman Yaylaz, Ferda Paçal, Ayşegül Ünüvar, Melda Sarıman, Ahmet Emre Eskazan, Serap Karaman, Ayşe Salihoğlu, Zeynep Karakaş, Neslihan Abacı, Sema Sırma Ekmekçi
Upregulation of SPINK2 in acute myeloid leukemia. Advances in laboratory medicine 4 (1) (2023)
Eren Arslan Davulcu, Merve Beyza Oğuz, Emre Kılıç, Ahmet Emre Eskazan
Treatment of anemia in myelofibrosis: focusing on Novel Therapeutic Options. Expert opinion on investigational drugs (2023)
Mehmet Baysal, Meltem Bayrak, Ahmet Emre Eskazan
Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Expert review of hematology 16 (2) (2023)
Guray Saydam, Rıdvan Ali, Ahmet Muzaffer Demir, Ahmet Emre Eskazan, Birol Guvenc, İbrahim Celallettin Haznedaroğlu, Mehmet Ali Ozcan, Ozan Salim, Mehmet Sonmez, Ayse Tulin Tuglular, Mehmet Turgut, Ali Unal, Birkan Aver, Sirac Bozkurt, Begum Ozdengulsun, Osman Ilhan
The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. International journal of hematologic oncology 11 (1) (2022)
Necati Alp Kılıçaslan, Şermin Börekci, Gül Nihal Özdemir, Muge Sayitoglu, Ahmet Emre Eskazan
Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame? Expert review of respiratory medicine 16 (8) (2022)
Betül Çanak, Ahmet Emre Eskazan
Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease. British journal of clinical pharmacology 88 (6) (2022)
Umut Yılmaz, Batuhan Bulan, Çağrı Belli, Ahmet Emre Eskazan
Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review. Expert review of hematology 15 (5) (2022)
Murat Özbalak, Metban Güzel Mastanzade, Özden Özlük, Tarık Onur Tiryaki, Sevgi Kalayoğlu-Beşışık, Ezgi Pınar Özbalak, Tuğrul Elverdi, Ipek Yonal Hindilerden, Ali Yılmaz Altay, Gulcin Yegen, Ahmet Emre Eskazan, Muhlis Cem Ar, Mustafa Nuri Yenerel, Teoman Soysal, Meliha Nalçacı, Burhan Ferhanoğlu, Sevgi Kalayoglu Besisik
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience Turkish journal of haematology : official journal of Turkish Society of Haematology 39 (4) (2022)
Simay Çokgezer, Tuğrul Elverdi, Ayşe Salihoğlu, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Ahmet Emre Eskazan
Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged ≥50 Years: A Single-Center Experience Over Two Decades. Cancer management and research 14 (2022)
Ahmet Emre Eskazan, Rıdvan Ali, Ebru Alnıgeniş, Orhan Ayyıldız, İbrahim Haznedaroğlu, Onur Kırkızlar, Erdal Kurtoğlu, Simten Malhan, Ergun Oksuz, Özlem Polat, Güray Saydam, Mehmet Sönmez, Selami Koçak Toprak, Tayfur Toptaş, Mehmet Turgut
Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert review of hematology 15 (2) (2022)
Zehra Narlı Özdemir, Necati Alp Kılıçaslan, Musa Yılmaz, Ahmet Emre Eskazan
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. International journal of hematology (2022)
Ahmet Emre Eskazan
Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate! Cancer (2022)
Tuğrul Elverdi, Mustafa Furkan Hıyamlı, Betül Şahin, Ahmet Emre Eskazan
A new dawn for upfront autologous SCT in NK/T-cell lymphomas: One more step forward in reasoning. International journal of cancer 151 (5) (2022)
Abdülkadir Erçalışkan, Fatma Zehra Avcı, Ahmet Emre Eskazan
Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia Turkish journal of haematology : official journal of Turkish Society of Haematology 39 (4) (2022)
Özge Sönmez, Selin Küçükyurt, Ayşe Mine Önenerk Men, Ahu Senem Demiröz, Ahmet Emre Eskazan
A Rare and Aggressive Disease: Answer. The American Journal of dermatopathology 44 (8) (2022)
Tahacan Aydın, Tuğrul Elverdi, Melis Dila Özer Çerme, Ahmet Emre Eskazan
Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al. Journal of thrombosis and haemostasis : JTH 19 (10) (2021)
Ahmet Emre Eskazan
A clinical appraisal of chronic myeloid leukaemia (CML)-related death and CML-specific death-Are they synonymous? International journal of clinical practice 75 (6) (2021)
Melikşah Bayar, Nurgül Özgür Yurttaş, Seçkin Bilgiç, Kebire Karakuş, Uğur Önal, Kerim Sönmezoğlu, Zafer Başlar, Ahmet Emre Eskazan
Candida esophagitis incidentally detected by 18F-FDG PET/CT in a patient with CNS lymphoma. Clinical case reports 9 (5) (2021)
Sara Malik, Shahzeb Hassan, Ahmet Emre Eskazan
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert review of hematology (2021)
Mebrure Burçak Yüzbaşıoğlu, Ahmet Emre Eskazan
Bosutinib - related pleural effusion in patients with chronic myeloid leukemia. Expert opinion on drug safety 20 (4) (2021)
Ahmet Emre Eskazan
Asciminib in chronic myeloid leukemia: many questions still remain to be answered. Blood cancer journal 11 (4) (2021)
Abdülkadir Erçalışkan, Duygu Seyhan Erdoğan, Ahmet Emre Eskazan
Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood advances 5 (17) (2021)
Sinem Nihal Esatoglu, Dilek Keskin, Ahmet Emre Eskazan, Tuğrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Yildiz Aydin, Hafize Uzun, Teoman Soysal
The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia Turkish journal of medical sciences 51 (1) (2021)
Betül İbiş, Mario Tiribelli, Ahmet Emre Eskazan
Asciminib as a new option in the treatment of chronic myeloid leukemia. Future oncology (London, England) 17 (36) (2021)
Tuğrul Elverdi, Melis Dila Özer Çerme, Tahacan Aydın, Ahmet Emre Eskazan
Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy? Expert review of clinical pharmacology 14 (10) (2021)
Ahmet Emre Eskazan, Ayşegül Gündüz
What is the best treatment approach for sporadic late-onset nemaline myopathy associated with "monoclonal gammopathy of neurological significance"? International journal of cancer 148 (11) (2021)
Muhammed Osman Corbali, Ahmet Emre Eskazan
Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML. Future oncology (London, England) 16 (14) (2020)
Abdulkadir Ercaliskan, Ahmet Emre Eskazan
Bosutinib - an effective and safe treatment option in the management of chronic myeloid leukemia. Future oncology (London, England) (2020)
Nilay Sengul Samanci, Umut Yılmaz, Sahin Bedir, Nurgul Ozgur Yurttas, Kerem Oruc, Zehra Durak Sahin, Emir Celik, Kubra Nur Toplutas, Hilal Akı, Ahmet Emre Eskazan, Fuat Hulusi Demirelli
Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (8) (2020)
Selin Kucukyurt, Yeliz Yagiz Ozogul, Abdülkadir Erçalışkan, Levent Kabasakal, Ahmet Emre Eskazan
Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor. Cancer reports (Hoboken, N.J.) 3 (5) (2020)
Ahmet Emre Eskazan
Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia? Leukemia 34 (12) (2020)
Mert Öztaş, Ilkın Muradov, Abdülkadir Erçalışkan, Ahu Senem Demiröz, Sebnem Batur, Ahmet Emre Eskazan, Serdal Uğurlu
Giant Cell Arteritis with Concomitant Chronic Myelomonocytic Leukemia Turkish journal of haematology : official journal of Turkish Society of Haematology 38 (3) (2020)
Umut Yılmaz, Aslıhan Pekmezci, Yalçın Gül, Ahmet Emre Eskazan
COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey Turkish journal of haematology : official journal of Turkish Society of Haematology 38 (1) (2020)
Nurgul Ozgur Yurttas, Ahmet Emre Eskazan
Tyrosine Kinase Inhibitor-Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact? Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 25 (2020)
Ahmet Murt, Ahmet Emre Eskazan, Umut Yılmaz, Tuba Ozkan, Muhlis Cem Ar
COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature. Journal of medical virology 93 (1) (2020)
Ahmet Emre Eskazan
Platelet count threshold for lumbar puncture: Does one size really fit all? Transfusion 61 (1) (2020)
Ahmet Emre Eskazan
Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic. British journal of clinical pharmacology 86 (9) (2020)
Selin Kucukyurt, Ahmet Emre Eskazan
Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes. Journal of blood medicine 11 (2020)
Emrah Yücesan, Ozden Hatirnaz Ng, Fevzi Firat Yalniz, Hulya Yilmaz, Ayse Salihoglu, Tugce Sudutan, Ahmet Emre Eskazan, Şeniz Öngören, Zafer Baslar, Teoman Soysal, Ugur Özbek, Muge Sayitoglu, Muhlis Cem Ar
Copy-number variations in adult patients with chronic immune thrombocytopenia. Expert review of hematology 13 (11) (2020)
Umut Yilmaz, Ahmet Emre Eskazan
Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years? Expert review of hematology 13 (10) (2020)
Ahmad Kunbaz, Ahmet Emre Eskazan
An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission. Expert review of hematology 12 (7) (2019)
Selin Kucukyurt, Ahmet Emre Eskazan
New drugs approved for acute myeloid leukaemia in 2018. British journal of clinical pharmacology 85 (12) (2019)
Ahmet Emre Eskazan
Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest? British journal of clinical pharmacology 85 (10) (2019)
Mario Tiribelli, Ahmet Emre Eskazan
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia. Oncology and therapy 7 (2) (2019)
Ahmet Emre Eskazan
Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia? Leukemia & lymphoma 60 (8) (2019)
Umut Yilmaz, Ahmet Emre Eskazan
Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective? Cancer 126 (2) (2019)
Tugce Eskazan, Salime Pelin Erturkuner, Basak Isildar, Ahmet Emre Eskazan, Muhlis Cem Ar, Kadri Atay, Zafer Baslar, Mustafa Tasyurekli
Coexistence of Hermansky-Pudlak syndrome and JAK2V617F-positive essential thrombocythemia. Ultrastructural pathology 43 (1) (2019)
Ahmet Emre Eskazan
Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes? British journal of clinical pharmacology 84 (8) (2018)
Abdulkadir Ercaliskan, Ahmet Emre Eskazan
The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer 124 (19) (2018)
Ahmet Emre Eskazan
Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword. Acta oncologica (Stockholm, Sweden) 58 (1) (2018)
Ahmet Emre Eskazan
The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis. Journal of medical economics 21 (7) (2018)
Ahmet Emre Eskazan
Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it? Cancer 124 (21) (2018)
Nurgül Özgür Yurttaş, Ahmet Emre Eskazan
Dasatinib-induced pulmonary arterial hypertension. British journal of clinical pharmacology 84 (5) (2018)
Yücel Erbilgin, Ahmet Emre Eskazan, Ozden Hatirnaz Ng, Ayse Salihoglu, Tugrul Elverdi, Sinem Firtina, Orcun Tasar, Sevcan Mercan, Sinem Sisko, Khusan Khodzhaev, Seniz Ongoren, Muhlis Cem Ar, Zafer Baslar, Teoman Soysal, Muge Sayitoglu, Ugur Ozbek
Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leukemia & lymphoma 60 (1) (2018)
Ahmet Emre Eskazan, Deniz Ozmen
Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good? Expert review of hematology 10 (7) (2017)
Seniz Ongoren, Ahmet Emre Eskazan, Veysel Suzan, Sercan Savci, Isil Erdogan Ozunal, Selin Berk, Fevzi Fırat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Yucel Erbilgin, Sibel Aylin Iseri, Muhlis Cem Ar, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek, Teoman Soysal
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology (Amsterdam, Netherlands) 23 (4) (2017)
Ahmet Emre Eskazan
Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib. International journal of clinical oncology 23 (2) (2017)
Ahmet Emre Eskazan, Muhlis Cem Ar, Teoman Soysal
Comment and response to: the significance of early warning in chronic myeloid leukemia. Expert review of hematology 11 (4) (2017)
Ahmet Emre Eskazan
Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Leukemia & lymphoma 58 (10) (2017)
Ahmet Emre Eskazan
Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. Annals of hematology 95 (11) (2016)
Ahmet Emre Eskazan
Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting. European journal of clinical pharmacology 72 (12) (2016)

Ahmet Emre Eskazan.css-eqlu8i{font-size:small;padding-left:4px;} (A Emre Eskazan, Ahmet Emre Eşkazan)

Publication Activity (10 Years)

Top Topics

Top Venues

Ahmet Emre Eskazan (A Emre Eskazan, Ahmet Emre Eşkazan)